Mechanism of Lesser Galangal Rhizome in the Treatment of Chronic Atrophic Gastritis Based on Network Pharmacology and Molecular Docking Technology
Objective To analyze the mechanism of lesser galangal rhizome in the treatment of chronic gastritis by network pharmacology and molecular docking technology.Methods The active components of lesser galangal rhizome were obtained through the Traditional Chinese Medicine Systems Pharmacology Database(TCMSP),and the target of lesser galangal rhizome was screened out to construct the regulation network of traditional Chinese medicine.By collecting the genes related to chronic atrophic gastritis in the database,the VENN map was drawn by gene merging.The obtained drug-related targets and disease-related targets were mapped and screened to obtain relevant intersection targets,and a PPI network was constructed to perform GO and KEGG enrichment analysis.Finally,Vina software was used to verify the molecular docking experiment for visual analysis.Results Through network pharmacology and molecular docking technology,13 active components of lesser galangal rhizome were obtained,and 85 targets were intersected with chronic atrophic gastritis.The protein interaction network was constructed to obtain the core genes including FOS,MYC,MAPK1,etc.,and the core drug components mainly include quercetin.GO analysis showed that biological functions mainly involved the response to cadmium ions.KEGG analysis showed that the pathway of lesser galangal rhizome in treatment of chronic atrophic gastritis mainly involved IL-17 signaling pathway,TNF signaling pathway,Toll-like receptor signaling pathway,etc.,in order to regulate the proliferation and apoptosis of gastric mucosal cells.In turn,it played a role in the treatment of chronic atrophic gastritis,improved the therapeutic effect of drugs,reduced toxic and side effects,and provided new ideas for further research on the mechanism of lesser galangal rhizome in the treatment of chronic atrophic gastritis.Conclusion Lesser galangal rhizome through multi-component,multi-target and multi-pathway in treatment of chronic atrophic gastritis,but further experimental or clinical verification is still needed.
万方数据
维普
